Drug Patent Expirations 2026-2030: The Patent Cliff
Published April 1, 2026 · USPTO patent data
The pharmaceutical industry faces its largest patent cliff in history. Over $200 billion in branded drug revenue will be exposed to generic and biosimilar competition between 2026 and 2030. For patients, this means dramatically lower prices on some of the most expensive medications. For pharma companies, it means a scramble to replace lost revenue.
Patent Cliff Timeline
| Year | Key Drugs at Risk | Est. Revenue at Risk | Impact |
|---|---|---|---|
| 2026 | Multiple immunology blockbusters | $45-55B | Biosimilar wave begins |
| 2027 | Oncology + diabetes treatments | $35-45B | Generic entry accelerates |
| 2028 | Respiratory + cardiology drugs | $30-40B | Price competition intensifies |
| 2029 | CNS + specialty pharma | $25-35B | Second biosimilar wave |
| 2030 | Additional oncology patents | $20-30B | Cumulative impact peaks |
Why This Cliff Is Different
Previous patent cliffs (2011-2015 with Lipitor, Plavix, Singulair) primarily affected small-molecule drugs where generic competition was straightforward. The 2026-2030 cliff includes many biologic drugs, where biosimilar competition is more complex, slower to develop, and results in smaller price reductions. However, the sheer volume of revenue at risk makes this the largest cliff ever.
Winners and Losers
- Generic/biosimilar manufacturers: Companies like Teva, Sandoz, and Viatris are positioned to capture significant market share as patents expire.
- Patients and payers: Drug costs should decline meaningfully in categories where patents expire, potentially saving the healthcare system tens of billions annually.
- Branded pharma: Companies most exposed will need to replace revenue through new launches, acquisitions, or lifecycle management strategies.
Explore individual drug patent timelines on our 2026 expirations page. For company-level analysis, see strongest patent portfolios. For how expiration works, see what happens when a patent expires.
Frequently Asked Questions
What is the patent cliff?
The patent cliff refers to the period when multiple blockbuster drug patents expire in rapid succession, exposing hundreds of billions in branded drug revenue to generic competition. The 2026-2030 period is considered one of the largest patent cliffs in pharmaceutical history.
What happens when a drug patent expires?
When a drug patent expires, generic manufacturers can produce and sell bioequivalent versions at much lower prices. Branded drug prices typically drop 80-90% within two years of the first generic entry. For biologics, biosimilar competition typically reduces prices 30-50%.
Which drugs are losing patent protection?
Major drugs facing patent expiration from 2026-2030 include several blockbuster immunology, oncology, and diabetes treatments. The combined annual revenue of drugs losing exclusivity in this window exceeds $200 billion.
About This Data
Patent data from USPTO PatentsView API. Revenue estimates from public financial filings. See our methodology.